TY - JOUR
T1 - Role of apomorphine in the treatment of Parkinson's Disease
AU - Boyle, Allison
AU - Ondo, William G.
N1 - Publisher Copyright:
© 2015 Springer International Publishing Switzerland.
PY - 2015/2
Y1 - 2015/2
N2 - Current research shows that apomorphine is an effective treatment for symptoms of Parkinson's Disease (PD). The highly lipophilic structure allows apomorphine to cross cell membranes rapidly, leading to the rapid onset of action for on/off symptoms of PD. The use of apomorphine was limited in the past due to peripheral side effects, but with the advent of better delivery systems and medications to control side effects, apomorphine is better tolerated and more widely in use. The major delivery systems are continuous subcutaneous infusions and intermittent subcutaneous injections, but other delivery routes are under investigation. The purpose of this article is to discuss the current use of apomorphine, the current delivery systems and to discuss future research.
AB - Current research shows that apomorphine is an effective treatment for symptoms of Parkinson's Disease (PD). The highly lipophilic structure allows apomorphine to cross cell membranes rapidly, leading to the rapid onset of action for on/off symptoms of PD. The use of apomorphine was limited in the past due to peripheral side effects, but with the advent of better delivery systems and medications to control side effects, apomorphine is better tolerated and more widely in use. The major delivery systems are continuous subcutaneous infusions and intermittent subcutaneous injections, but other delivery routes are under investigation. The purpose of this article is to discuss the current use of apomorphine, the current delivery systems and to discuss future research.
UR - http://www.scopus.com/inward/record.url?scp=84925522129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925522129&partnerID=8YFLogxK
U2 - 10.1007/s40263-014-0221-z
DO - 10.1007/s40263-014-0221-z
M3 - Article
C2 - 25676564
AN - SCOPUS:84925522129
SN - 1172-7047
VL - 29
SP - 83
EP - 89
JO - CNS Drugs
JF - CNS Drugs
IS - 2
ER -